Filtered By:
Source: CardioBrief
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 307 results found since Jan 2013.
No Increase In Diabetes Found With Ezetimibe In IMPROVE-IT
A new analysis of the IMPROVE-IT trial found no significant increase in the rate of new onset diabetes in patients taking ezetimibe. Michael Blazing of Duke University presented the results of the IMPROVE-IT substudy on Tuesday afternoon at the European Society of Cardiology meeting in London. The analysis was prompted by previous findings from very...Click here to continue reading...
Source: CardioBrief - September 1, 2015 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol diabetes ezetimibe IMPROVE-IT Simvastatin Source Type: blogs
Califf, Nissen, And Others Agree And Disagree About Regulatory Standards
Everyone agrees. A panel of US and European cardiologists, regulators, and industry executives agreed broadly that regulatory standards for drugs and devices need to be rigorous enough to prevent harm to patients. And, they also agreed, the standards shouldn’t be so strict that they stifle innovation. The problem, of course, is how to find the right...Click here to continue reading...
Source: CardioBrief - September 1, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Califf devices drugs EMA FDA Nissen renal denervation Source Type: blogs
IMPROVE-IT Substudy: Ezetimibe Benefit Restricted To Diabetics
The beneficial effects of ezetimibe are found almost exclusively in patients with diabetes, according to an update of the influential IMPROVE-IT trial presented on Sunday at the European Society of Cardiology meeting in London. The new finding may lead to questions about the widely accepted interpretation of the main finding of the trial, which is that it provided strong support for...Click here to continue reading...
Source: CardioBrief - August 31, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Uncategorized diabetes ezetimibe IMPROVE-IT LDL vytorin Source Type: blogs
Hot Lines, Simultaneous Publications, And The Decline Of Medical Meetings
Back in the Dark Ages when I covered big medical conferences (like the European Society of Cardiology meeting now getting underway in London) it was necessary to attend the sessions, roam the halls, and talk to doctors. There were no late-breaking or hot line sessions and there were certainly no simultaneous publications in journals. (If memory...Click here to continue reading...
Source: CardioBrief - August 29, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics ACC AHA conferences ESC Hot Lines NEJM Source Type: blogs
ESC 2015 Set To Start In London
The European Society of Cardiology meeting starts this weekend in London. Merrie Olde Englande? Industry will be here too. ...Click here to continue reading...
Source: CardioBrief - August 28, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Uncategorized ESC London Novartis Sanofi Source Type: blogs
Ignorance, Cardiology, And The Milky Way Galaxy
Question: How is the Milky Way Galaxy like cardiology (and the rest of medicine and science)? Answer: Sometimes we think we know a lot more about them than we really do. I remember staring at the page of my third grade science textbook. We were learning about astronomy and the Milky Way galaxy. There was...Click here to continue reading...
Source: CardioBrief - August 25, 2015 Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics ignorance science Source Type: blogs
What Role Should Coca-Cola Play In Obesity Research?
The New York Times reports that Coca-Cola gives financial support to scientists and a new foundation to help promote the message that the obesity epidemic is fueled not by too many calories or too much sugar but by not enough physical activity. The Times piece is well worth a read but the issue it takes up is not new. Last year I wrote a long post which included an interview with a scientist, Carl Lavie, a Louisiana cardiologist who is a frequent co-author of Steven Blair, another researcher who is the main focus of the Times story. My post from last year is reprinted below. But first More…
Source: CardioBrief - August 9, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Carl Lavie Coca Cola exercise New York Times obesity Steven Blair Source Type: blogs
$300 Millions Dollars Of Cardiology Sunshine
$300 million dollars. That’s how much industry paid to cardiologists and other related healthcare professionals between August 2013 and December 2014… … Click here to read my entire story on MedPage Today.
Source: CardioBrief - July 24, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Uncategorized CMS Open Payments ProPublica Sunshine Act Source Type: blogs
Can You Test A Drug And Also Say Negative Things About It?
In my last post I raised the possibility that Steve Nissen, a highly influential cardiologist who has been an outspoken critic of industry influence in medicine, might have his own conflict of interest (COI) problem. In response, another cardiologist, James Stein, said that my post was unfair in its treatment of Nissen and failed to consider important distinctions and subtleties in the academic literature about conflict of interest. Let me first of all confess that Stein– for whom I have the highest possible regard– makes some excellent points. And I further admit that my piece More…
Source: CardioBrief - June 15, 2015 Category: Cardiology Authors: Larry Husten Tags: People Policy & Ethics CME conflict of interest PCSK9 steve nissen Source Type: blogs
Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs
Does Steve Nissen, an outspoken critic of inappropriate industry influence in medicine, have his own conflict of interest problem? This week Nissen, the chief of cardiology at the Cleveland Clinic, was widely quoted in news reports about the FDA advisory panels evaluating two new highly promising cholesterol drugs from Amgen and Sanofi/Regeneron. Nissen was broadly supportive of the drugs. Although he has been one of the leading voices against approving and using drugs based solely on their effect on surrogate outcomes, he was much more liberal about these drugs than some other experts and many of the panel members. H...
Source: CardioBrief - June 12, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics conflict of interest FDA Nissen PCSK9 Source Type: blogs
Another One Bites The Dust: On The Death Of A Social Media Site For Doctors
Like a certain late lamented parrot, CardioExchange is no more. It has ceased to be. The website was started by the New England Journal of Medicine and the Massachusetts Medical Society more than 5 years ago in the wake of the explosive and ubiquitous growth of social media. But the rise of social media also provoked tremendous uncertainty and even anxiety over its role in healthcare and medicine. In response to this major transformation of the media landscape, MMS and NEJM launched CardioExchange as an experiment in social media for cardiologists and other healthcare professionals interested in cardiovascu...
Source: CardioBrief - June 4, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Uncategorized CardioExchange new england journal of medicine social media Source Type: blogs
Novartis’ Summer Blockbuster LCZ696 Gains A Name, Skips An Advisory Panel
Entresto. That’s the brand name Novartis has chosen for LCZ696, its new heart failure drug that is expected to be a blockbuster. The name won’t be final until official confirmation, which comes with FDA approval. But Novartis will introduce the name for the first time this weekend in presentations at the European Society of Cardiology Heart Failure meeting in Seville, Spain. FDA approval of Entresto is expected to occur by August at the latest. There are no apparent roadblocks to approval since Novartis has stated that it doesn’t expect an FDA advisory panel. Approval might well come earl...
Source: CardioBrief - May 22, 2015 Category: Cardiology Authors: Larry Husten Tags: Heart Failure People, Places & Events Entresto FDA LCZ696 Novartis Source Type: blogs
Prominent Harvard Cardiologist Moves To Google X To Head Large Study
Here’s a clear sign of the ascending role of digital/precision/personalized medicine: a prominent cardiologist has left a top academic and clinical position in Boston to run a large, innovative study in Silicon Valley. Jessica Mega was widely perceived as a rising star at Harvard Medical School and the Brigham and Women’s Hospital. She has now joined Google X, Google’s research arm, where she will head up the much publicized Baseline Study. “I’m jealous,” said one academic cardiologist at a top hospital, upon hearing the news. Baseline is one of the ambitious projects undertaken ...
Source: CardioBrief - May 11, 2015 Category: Cardiology Authors: Larry Husten Tags: People, Places & Events Policy & Ethics Prevention, Epidemiology & Outcomes Baseline Study genetics Google precision medicine Source Type: blogs
No Benefit For A Commonly Used Cardiac Device
Once again, after decades of common use, a frequently implanted device has been found to confer no benefit whatsoever over a much less invasive therapy. Cardiologists and radiologists often implant the device, called a retrievable inferior vena cava filter, inside people who are at high risk for developing potentially lethal blood clots. The filter is designed to prevent pulmonary embolism, an extremely dangerous condition that occurs when a blood clot from the legs migrates into the lungs. Now a new study published in JAMA shows that these devices provide no advantage over anticoagulant drugs which thin the blood....
Source: CardioBrief - April 29, 2015 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes blood clots inferior vena cava filters pulmonary embolism venous thromboembolism Source Type: blogs
Medicines Company Drug Finally Gets Nod From FDA Advisory Panel
On Wednesday the FDA’s Cardiovascular and Renal Drugs Advisory Committee voted 9-2-1 to recommend approval of cangrelor during PCI to reduce the risk of periprocedural thrombotic events such as MI, stent thrombosis, and ischemia driven revascularization. … Click here to read the full post on Forbes.
Source: CardioBrief - April 16, 2015 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Policy & Ethics ad hoc PCI Cangrelor FDA Medicines Company Source Type: blogs
